Step 1: Match the Pitch to a Public Record
Start with identity. Does the message name a sponsoring organization, a site, and a contact of record, or only a generic "research team"? Ask whether the study has a public registry record and what identifier it uses. Compare the title, condition, sponsor, and site. A flyer saying "diabetes study" can describe a different study from the record you found.
A registry lookup is an identity check, not proof of quality. If the listing cannot be matched, ask for the study title used on the consent form. Unanswered calls and changing titles are process problems, not reasons to keep guessing. Checkpoint: can you name the sponsor, site, and record?
Step 2: Read the Phase Label Without Over-Reading It
A phase label places the study at a stage of a research program. It does not predict your personal chance of benefit and should not be used to rank studies as "best" or "safest." Turn the label into a question: what is this protocol designed to learn, what will be measured, and what will participants do?
Ask: Is there a comparison group? What has already been tested in people with diabetes? Do not accept "it is Phase X, so it is advanced" as an answer. A phase number is not a prognosis. If staff cannot explain the protocol's purpose plainly, record that difficulty.
Step 3: Treat Eligibility as a Line-by-Line Screen
Eligibility criteria are gates, not a verdict on your health. Read inclusion and exclusion lines verbatim. Categories may include age, diabetes type, current medicines, recent laboratory results, other conditions, and pregnancy plans. One criterion can exclude an otherwise suitable person; that is how screening works, not evidence that you failed as a patient.
Do not ask only "Do I qualify?" Ask which specific criterion you did not meet, whether it is absolute, and what documentation is required. If turned down without explanation, request the criterion in writing. You may fit a different study, but this listing has decided. Checkpoint: can you point to the line that includes or excludes you?
Step 4: Understand Randomization and Your Current Medication
Randomization means assignment by chance, not by your preference or your doctor's. Blinding means you or staff may not know your group. A comparison group may receive placebo, usual care, or another treatment; the consent form should state what is possible. The practical question is what happens to the regimen you already rely on.
Ask whether your current diabetes medicines continue unchanged, could be adjusted, or would stop. Ask who manages high or low glucose and which care is study-related versus routine. Do not assume joining means stopping your medication, or that it means continuing it. Get answers from the protocol team and your clinician.
Step 5: Map Visits, Monitoring, and Cost Questions
A short recruitment window can hide a long visit schedule. Ask for the number and length of visits, study duration, and whether scheduling can accommodate work. Ask about fingersticks, continuous glucose monitoring, downloads, diaries, and who supplies equipment. Ask about travel, parking, and any documented reimbursement.
Cost wording matters: which procedures does the study pay for, which are billed to insurance, and which become your responsibility? Coverage varies by study and institution. Request the written explanation rather than a recruiter's summary. Vague answers are useful information: you have not reached a decision point.
Step 6: Spot Recruitment Language That Overpromises
You do not need to be a researcher to notice a sales pitch. Google's Publisher Policies prohibit content that promotes harmful health claims or contradicts authoritative scientific consensus, and prohibit misrepresentation about the content or its purpose. Its compliance material treats concrete promises that cannot be fulfilled—free or cash offers and specific promises outside the publisher's control—as egregious violations. These standards govern advertising, not medical care, but they are a useful benchmark.
Treat these as stop signs: guaranteed cure or "better control" for every participant; absolute "free treatment" with no written coverage; urgency that discourages reading consent; no sponsor, site, contact, or record; or pay-to-join and product-sale requests. The same policy set restricts online sale of prescription drugs and promotion of unapproved drugs or supplements, including supplements containing active drug ingredients. A message that drifts into selling a product is no longer a study listing you can evaluate on its merits.
Step 7: Use the Screening Call to Test Fit
Write three questions before calling: What is the study asking? Which criterion is most likely to exclude me? What would my visit and monitoring schedule be? Add: Who is my contact of record, and where is the consent document? Screening is a conversation, not enrollment; you can decline and ask for time to review consent with your diabetes care team.
The study team—not this article—decides eligibility. No article can tell you whether you qualify, whether the study will help, or what it will cost. Those answers come from the protocol team, the consent document, and your own clinician.
What This Filter Cannot Tell You
This is U.S.-focused general information, not medical advice. Availability, criteria, visit schedules, and cost coverage change and differ by study and institution, so verify current details at the source. This article deliberately names no trial, phase threshold, payment amount, or outcome because the research materials for this piece contained publisher-policy documents rather than trial-level data. If a listing cannot survive Step 1 or Step 6, stop; if it survives, bring your question list to the screening call and your care team.
研究の知恵